Ginkgo Stock Today

DNA -  USA Stock  

USD 9.74  1.09  12.60%

Market Performance
2 of 100
Odds Of Distress
Less than 46
Ginkgo Bioworks is trading at 9.74 as of the 7th of December 2021, a 12.60% increase since the beginning of the trading day. The stock's open price was 8.65. Ginkgo Bioworks has 46 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Ginkgo Bioworks Hldgs are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of September 2021 and ending today, the 7th of December 2021. Please note, there could be an existing legal relationship between Ginkgo Bioworks Hldgs (DNA) and Genentech (DNA1). Click here to learn more.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts. Ginkgo Bioworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 1.05 B outstanding shares of which 17.42 M shares are currently shorted by investors with about 1.7 days to cover. More on Ginkgo Bioworks Hldgs

Ginkgo Bioworks Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Ginkgo Bioworks' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ginkgo Bioworks or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Ginkgo Bioworks has very high historical volatility over the last 90 days
The company reported the last year's revenue of 197.4 M. Reported Net Loss for the year was (276.32 M) with profit before taxes, overhead, and interest of 61.05 M.
Ginkgo Bioworks Hldgs has about 1.74 B in cash with (147.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.17.
Ginkgo Bioworks has a frail financial position based on the latest SEC disclosures
Over 76.0% of the company shares are held by institutions such as insurance companies
Latest headline from 41 Stocks Moving In Fridays Mid-Day Session - Benzinga - Benzinga
Ginkgo Bioworks Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Ginkgo Bioworks Hldgs SEC Filings
Ginkgo Bioworks SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameGinkgo Bioworks Hldgs
Related EntityDNA1 (Genentech)
CEOKenny Goh  (View All)
Thematic Classifications
Active investing themes Ginkgo currently participates. (view all). An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Average Analyst Recommendation
Analysts covering Ginkgo Bioworks report their recommendations after researching Ginkgo Bioworks' financial statements, talking to executives and customers, or listening in on Ginkgo Bioworks' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Ginkgo Bioworks Hldgs. The Ginkgo consensus assessment is calculated by taking the average forecast from all of the analysts covering Ginkgo Bioworks.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Ginkgo Bioworks Hldgs based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Ginkgo Bioworks Hldgs financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares8.6 M7.8 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted8.6 M7.8 M
Significantly Up
Slightly volatile
Total Assets644.3 M675.2 M
Sufficiently Down
Slightly volatile
Total Liabilities223.9 M205.1 M
Significantly Up
Slightly volatile
Current Assets422.1 M426.5 M
Fairly Down
Slightly volatile
Current Liabilities71.3 M73.2 M
Fairly Down
Slightly volatile
Total Debt15.7 M16.5 M
Notably Down
Slightly volatile
Gross Margin0.80.796
Slightly Up
Slightly volatile
Asset Turnover0.09890.1
Fairly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Ginkgo Bioworks' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Ginkgo Bioworks' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Ginkgo Bioworks' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ginkgo Bioworks' financial leverage. It provides some insight into what part of Ginkgo Bioworks' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Ginkgo Bioworks' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Ginkgo Bioworks deploys its capital and how much of that capital is borrowed.
Ginkgo Bioworks Hldgs (DNA) is traded on New York Stock Exchange in USA. It is located in 27 Drydock Avenue and employs 495 people. Ginkgo Bioworks is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with total capitalization of 87.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ginkgo Bioworks's market, we take the total number of its shares issued and multiply it by Ginkgo Bioworks's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Ginkgo Bioworks Hldgs runs under Healthcare sector within Biotechnology industry. The entity has 1.05 B outstanding shares of which 17.42 M shares are currently shorted by investors with about 1.7 days to cover. Ginkgo Bioworks Hldgs has about 1.74 B in cash with (147.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.17.
Check Ginkgo Bioworks Probability Of Bankruptcy
Ginkgo Bioworks secures a total of 1.05 Billion outstanding shares. The majority of Ginkgo Bioworks Hldgs outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ginkgo Bioworks to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ginkgo Bioworks Hldgs. Please pay attention to any change in the institutional holdings of Ginkgo Bioworks Hldgs as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Ginkgo Ownership Details

Ginkgo Stock Price Odds Analysis

What are Ginkgo Bioworks' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Ginkgo Bioworks jumping above the current price in 90 days from now is about 92.75%. The Ginkgo Bioworks Hldgs probability density function shows the probability of Ginkgo Bioworks stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.0691 suggesting Ginkgo Bioworks Hldgs market returns are sensitive to returns on the market. As the market goes up or down, Ginkgo Bioworks is expected to follow. Additionally, the company has an alpha of 0.033, implying that it can generate a 0.033 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 9.74HorizonTargetOdds Up 9.74 
7.21%90 days
Based on a normal probability distribution, the odds of Ginkgo Bioworks to move above the current price in 90 days from now is about 92.75 (This Ginkgo Bioworks Hldgs probability density function shows the probability of Ginkgo Stock to fall within a particular range of prices over 90 days) .

Ginkgo Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Ginkgo Bioworks that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ginkgo Bioworks' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ginkgo Bioworks' value.
InstituionSecurity TypeTotal SharesValue
Viking Global Investors LpCommon Shares302.9 M3.5 B
General Atlantic LpCommon Shares114.9 M1.3 B
View Ginkgo Bioworks Diagnostics

Ginkgo Bioworks Historical Income Statement

Ginkgo Bioworks Hldgs Income Statement is one of the three primary financial statements used for reporting Ginkgo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ginkgo Bioworks Hldgs revenue and expense. Ginkgo Bioworks Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More Fundamentals

Ginkgo Stock Against Markets

Picking the right benchmark for Ginkgo Bioworks stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Ginkgo Bioworks stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Ginkgo Bioworks is critical whether you are bullish or bearish towards Ginkgo Bioworks Hldgs at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Ginkgo Bioworks without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Tickers Now


Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Ginkgo Bioworks Corporate Directors

Ginkgo Bioworks corporate directors refer to members of a Ginkgo Bioworks board of directors. The board of directors generally takes responsibility for the Ginkgo Bioworks' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Ginkgo Bioworks' board members must vote for the resolution. The Ginkgo Bioworks board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Somkiat Chuasiriphatthana - DirectorProfile
Suchet Sunthorawet - DirectorProfile
Sirisak Piyathatsikun - DirectorProfile
Benedict Reichel - Company Secretary, Executive DirectorProfile
Continue to Investing Opportunities. Note that the Ginkgo Bioworks Hldgs information on this page should be used as a complementary analysis to other Ginkgo Bioworks' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Ginkgo Stock analysis

When running Ginkgo Bioworks Hldgs price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Global Correlations
Find global opportunities by holding instruments from different markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Transaction History
View history of all your transactions and understand their impact on performance
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is Ginkgo Bioworks' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ginkgo Bioworks Hldgs is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine Ginkgo Bioworks value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.